Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             338 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus–poxvirus prime boost immunisations Ranasinghe, Charani
2011
29 Supplement 1 p. 3008-3020
13 p.
artikel
2 A computerized pneumococcal vaccination reminder system in the adult emergency department Dexheimer, Judith W.
2011
29 Supplement 1 p. 7035-7041
7 p.
artikel
3 Active immunization against IL-23p19 improves experimental arthritis Ratsimandresy, Rojo Anthony
2011
29 Supplement 1 p. 9329-9336
8 p.
artikel
4 Adverse event reports following Japanese encephalitis vaccination in the United States, 1999–2009 Lindsey, Nicole P.
2010
29 Supplement 1 p. 58-64
7 p.
artikel
5 Adverse events associated with pandemic influenza vaccines: Comparison of the results of a follow-up study with those coming from spontaneous reporting Carvajal, A.
2011
29 Supplement 1 p. 519-522
4 p.
artikel
6 Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces—2009–2010 Mayet, Aurélie
2011
29 Supplement 1 p. 2576-2581
6 p.
artikel
7 Afriflu—International conference on influenza disease burden in Africa, 1–2 June 2010, Marrakech, Morocco Steffen, C.
2011
29 Supplement 1 p. 363-369
7 p.
artikel
8 Age distribution of cases and deaths during the 1889 influenza pandemic Valtat, Sophie
2011
29 Supplement 1 p. B6-B10
nvt p.
artikel
9 Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques Carroll, Timothy D.
2011
29 Supplement 1 p. 931-940
10 p.
artikel
10 Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial Gudmundsdotter, L.
2011
29 Supplement 1 p. 5558-5566
9 p.
artikel
11 A mucosal vaccination approach for herpes simplex virus type 2 Tirabassi, Rebecca S.
2011
29 Supplement 1 p. 1090-1098
9 p.
artikel
12 Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease Nemirovsky, Anna
2011
29 Supplement 1 p. 4043-4050
8 p.
artikel
13 Analysis of porcine circovirus type 1 detected in Rotarix vaccine Baylis, Sally A.
2011
29 Supplement 1 p. 690-697
8 p.
artikel
14 An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions Ghunaim, Haitham
2011
29 Supplement 1 p. 5950-5958
9 p.
artikel
15 An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice Hu, Kai
2011
29 Supplement 1 p. 1455-1462
8 p.
artikel
16 An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults Talaat, Kawsar R.
2011
29 Supplement 1 p. 3144-3148
5 p.
artikel
17 A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors Wick, Darin A.
2011
29 Supplement 1 p. 7857-7866
10 p.
artikel
18 A novel broad-spectrum treatment for respiratory virus infections: Influenza-based defective interfering virus provides protection against pneumovirus infection in vivo Easton, Andrew J.
2011
29 Supplement 1 p. 2777-2784
8 p.
artikel
19 A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus Eliasson, Dubravka Grdic
2011
29 Supplement 1 p. 3951-3961
11 p.
artikel
20 A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations Yu, Mingke
2011
29 Supplement 1 p. 2429-2436
8 p.
artikel
21 Antibody- and cell-mediated immune responses to a synthetic oligosaccharide conjugate vaccine after booster immunization Safari, Dodi
2011
29 Supplement 1 p. 6498-6504
7 p.
artikel
22 Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation Cranage, Martin P.
2011
29 Supplement 1 p. 1421-1430
10 p.
artikel
23 Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations Gracia, Aleksandra
2011
29 Supplement 1 p. 1595-1604
10 p.
artikel
24 Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children Meier, Sara
2011
29 Supplement 1 p. 3548-3557
10 p.
artikel
25 Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset Suleman, Muhammad
2011
29 Supplement 1 p. 5892-5903
12 p.
artikel
26 Antigenic mimicry-mediated anti-prion effects induced by bacterial enzyme succinylarginine dihydrolase in mice Ishibashi, Daisuke
2011
29 Supplement 1 p. 9321-9328
8 p.
artikel
27 Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal vaccine containing lipid A Matyas, Gary R.
2011
29 Supplement 1 p. 5137-5144
8 p.
artikel
28 A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadravalent vaccine and their comparison with TETRAct-Hib vaccine in Indian infants aged 6–14 weeks Sharma, Hitt
2011
29 Supplement 1 p. 8773-8779
7 p.
artikel
29 A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients Staff, Caroline
2011
29 Supplement 1 p. 6817-6822
6 p.
artikel
30 A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects Keefer, Michael C.
2011
29 Supplement 1 p. 1948-1958
11 p.
artikel
31 A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression Keiser, P.B.
2011
29 Supplement 1 p. 1413-1420
8 p.
artikel
32 A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1 Tetteh, Kevin K.A.
2011
29 Supplement 1 p. 7811-7817
7 p.
artikel
33 A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years Tennis, Patricia
2011
29 Supplement 1 p. 4947-4952
6 p.
artikel
34 Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs Advani, Abdolreza
2011
29 Supplement 1 p. 3438-3442
5 p.
artikel
35 A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults Block, Stan L.
2011
29 Supplement 1 p. 9391-9397
7 p.
artikel
36 A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants Bernstein, David I.
2011
29 Supplement 1 p. 7042-7048
7 p.
artikel
37 A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years Schwarz, T.F.
2011
29 Supplement 1 p. 5195-5202
8 p.
artikel
38 ArtinM, a d-mannose-binding lectin from Artocarpus integrifolia, plays a potent adjuvant and immunostimulatory role in immunization against Neospora caninum Cardoso, Mariana R.D.
2011
29 Supplement 1 p. 9183-9193
11 p.
artikel
39 A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1 Koti, Madhuri
2011
29 Supplement 1 p. 7905-7912
8 p.
artikel
40 Assessment of the first HPV vaccination campaign in two northern Italian health districts Chadenier, G.M.C.
2011
29 Supplement 1 p. 4405-4408
4 p.
artikel
41 A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 – A GLURP–MSP3 fusion protein malaria vaccine candidate Lousada-Dietrich, Susana
2011
29 Supplement 1 p. 3284-3292
9 p.
artikel
42 Atopy history and the genomics of wheezing after influenza vaccination in children 6–59 months of age Miller, E. Kathryn
2011
29 Supplement 1 p. 3431-3437
7 p.
artikel
43 Attenuation of bovine herpesvirus type 1 by deletion of its glycoprotein G and tk genes and protection against virulent viral challenge Zhang, Minmin
2011
29 Supplement 1 p. 8943-8950
8 p.
artikel
44 Attitudinal and demographic predictors of measles, mumps and rubella (MMR) vaccine acceptance: Development and validation of an evidence-based measurement instrument Brown, Katrina F.
2011
29 Supplement 1 p. 1700-1709
10 p.
artikel
45 Barriers of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies Dhalla, Shayesta
2011
29 Supplement 1 p. 5850-5859
10 p.
artikel
46 Blinded, controlled field trial of two commercially available Mycoplasma bovis bacterin vaccines in veal calves Soehnlen, Marty K.
2011
29 Supplement 1 p. 5347-5354
8 p.
artikel
47 Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice Guler, Reto
2011
29 Supplement 1 p. 1339-1346
8 p.
artikel
48 Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies Pusic, Kae
2011
29 Supplement 1 p. 8898-8908
11 p.
artikel
49 Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania Bakari, Muhammad
2011
29 Supplement 1 p. 8417-8428
12 p.
artikel
50 Cancer vaccines and carbohydrate epitopes Heimburg-Molinaro, Jamie
2011
29 Supplement 1 p. 8802-8826
25 p.
artikel
51 Carriage of Haemophilus influenzae among Brazilian children attending day care centers in the era of widespread Hib vaccination de Carvalho, Camila Xavier
2011
29 Supplement 1 p. 1438-1442
5 p.
artikel
52 Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination Williams, S. Elizabeth
2011
29 Supplement 1 p. 8302-8308
7 p.
artikel
53 Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection García, Felipe
2011
29 Supplement 1 p. 6454-6463
10 p.
artikel
54 Changes in serotype distribution of Haemophilus influenzae meningitis isolates identified through laboratory-based surveillance following routine childhood vaccination against H. influenzae type b in Brazil Zanella, Rosemeire C.
2011
29 Supplement 1 p. 8937-8942
6 p.
artikel
55 Changing epidemiology of hepatitis A infection in Izmir, Turkey Kurugol, Zafer
2011
29 Supplement 1 p. 6259-6261
3 p.
artikel
56 Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines Westdijk, Janny
2011
29 Supplement 1 p. 3390-3397
8 p.
artikel
57 Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV Liu, Ye V.
2011
29 Supplement 1 p. 6606-6613
8 p.
artikel
58 Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function Odumosu, Oludare
2011
29 Supplement 1 p. 8451-8458
8 p.
artikel
59 Chronological study of cytokine transcription in the spleen and lung of chickens after vaccination with serotype 1 Marek's disease vaccines Gimeno, Isabel M.
2011
29 Supplement 1 p. 1583-1594
12 p.
artikel
60 Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: Randomized study in healthy girls Schmeink, Channa E.
2011
29 Supplement 1 p. 9276-9283
8 p.
artikel
61 Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates Safari, Dodi
2011
29 Supplement 1 p. 849-854
6 p.
artikel
62 Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides Denoël, Philippe
2011
29 Supplement 1 p. 6451-6453
3 p.
artikel
63 Comparative study of the immune effect of an Edwardsiella tarda antigen in two forms: Subunit vaccine vs DNA vaccine Sun, Yun
2011
29 Supplement 1 p. 2051-2057
7 p.
artikel
64 Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose Zheng, Hui
2011
29 Supplement 1 p. 9098-9103
6 p.
artikel
65 Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: Systematic review and meta-analysis Scott, Pippa
2011
29 Supplement 1 p. 9711-9721
11 p.
artikel
66 Comparison of influenza vaccine effectiveness using different methods of case detection: Clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) Coleman, Laura A.
2011
29 Supplement 1 p. 387-390
4 p.
artikel
67 Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults Frenck Jr., Robert W.
2011
29 Supplement 1 p. 5666-5674
9 p.
artikel
68 Contamination in bluetongue virus challenge experiments Eschbaumer, Michael
2011
29 Supplement 1 p. 4299-4301
3 p.
artikel
69 Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen Vu, David M.
2011
29 Supplement 1 p. 1968-1973
6 p.
artikel
70 Corrigendum to “Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers” [Vaccine 26 (2008) 6671–6677] Guimarães-Walker, A.
2011
29 Supplement 1 p. 3511-
1 p.
artikel
71 Coverage and side effects of influenza A(H1N1) 2009 monovalent vaccine among primary health care workers Arjona, Miguel Angel Ortiz
2011
29 Supplement 1 p. 6366-6368
3 p.
artikel
72 Current trend of pneumococcal serotypes distribution and antibiotic susceptibility pattern in Malaysian hospitals Rohani, Md Yasin
2011
29 Supplement 1 p. 5688-5693
6 p.
artikel
73 Dendritic cells expressing BTLA induces CD8+ T cell tolerance and attenuates the severity of diabetes Li, Shufa
2011
29 Supplement 1 p. 7747-7751
5 p.
artikel
74 Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity Wanjalla, Celestine N.
2010
29 Supplement 1 p. 130-140
11 p.
artikel
75 Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env Mattiacio, Jonelle
2011
29 Supplement 1 p. 2637-2647
11 p.
artikel
76 Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine Yen, Catherine
2011
29 Supplement 1 p. 4151-4155
5 p.
artikel
77 Determination of antigenic properties of vaccine derived poliovirus strains Pliaka, Vaia
2010
29 Supplement 1 p. 26-33
8 p.
artikel
78 Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 Fomsgaard, Anders
2011
29 Supplement 1 p. 7067-7074
8 p.
artikel
79 Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2 Posavad, Christine M.
2011
29 Supplement 1 p. 7058-7066
9 p.
artikel
80 Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever Osorio, Jorge E.
2011
29 Supplement 1 p. 7251-7260
10 p.
artikel
81 Development of pandemic influenza vaccine production capacity in Viet Nam Hoa, L.K.
2011
29 Supplement 1 p. A34-A36
nvt p.
artikel
82 Differences in the priming effect of various clades/subclades of inactivated H5N1 vaccine for booster injection with heterologous clades of vaccine strains Ikeno, Daisuke
2011
29 Supplement 1 p. 4156-4161
6 p.
artikel
83 Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines Pillai, Vinod Kumar Bhaskara
2011
29 Supplement 1 p. 5399-5406
8 p.
artikel
84 Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination Clarke, Michelle F.
2011
29 Supplement 1 p. 4663-4667
5 p.
artikel
85 Distribution, dynamics and antibiotic resistance patterns of Streptococcus pneumoniae serotypes causing acute otitis media in children in southern Israel during the 10 year-period before the introduction of the 7-valent pneumococcal conjugate vaccine Somech, Ido
2011
29 Supplement 1 p. 4202-4209
8 p.
artikel
86 Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates Marsh, Jane W.
2011
29 Supplement 1 p. 6049-6058
10 p.
artikel
87 DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge Lu, Yu-Chun
2011
29 Supplement 1 p. 7740-7746
7 p.
artikel
88 Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older Lode, H.
2011
29 Supplement 1 p. 4940-4946
7 p.
artikel
89 Do the initial serum level changes of sCD26 have ability to predict successful treatment with IFN-α among naïve chronic hepatitis B patients? Alavi-Moghaddam, Mostafa
2011
29 Supplement 1 p. 9093-9097
5 p.
artikel
90 Dynamics of Streptococcus pneumoniae nasopharyngeal carriage with high heptavalent pneumococcal conjugate vaccine coverage in Central Greece Grivea, Ioanna N.
2011
29 Supplement 1 p. 8882-8887
6 p.
artikel
91 Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and β-glucan Fredriksen, B.N.
2011
29 Supplement 1 p. 8338-8349
12 p.
artikel
92 Early immunocastration of male pigs with Improvac® – Effect on boar taint, hormones and reproductive organs Brunius, Carl
2011
29 Supplement 1 p. 9514-9520
7 p.
artikel
93 Economic analysis of the global polio eradication initiative Duintjer Tebbens, Radboud J.
2010
29 Supplement 1 p. 334-343
10 p.
artikel
94 Editorial Board 2011
29 Supplement 1 p. CO2-
1 p.
artikel
95 Editorial Board 2010
29 Supplement 1 p. CO2-
1 p.
artikel
96 Editorial Board/Aims and Scope 2011
29 Supplement 1 p. CO2-
1 p.
artikel
97 Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine Miller, Elizabeth
2011
29 Supplement 1 p. 9127-9131
5 p.
artikel
98 Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: Population-based case–control study Mahmud, Salaheddin
2011
29 Supplement 1 p. 7975-7981
7 p.
artikel
99 Effect of GonaCon™ vaccine on black-tailed prairie dogs: Immune response and health effects Yoder, Christi A.
2010
29 Supplement 1 p. 233-239
7 p.
artikel
100 Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal Shuaibu, M.N.
2011
29 Supplement 1 p. 3239-3247
9 p.
artikel
101 Effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the immune responses to Newcastle disease vaccine in chickens Zhai, Lijuan
2011
29 Supplement 1 p. 5007-5014
8 p.
artikel
102 Effect of thiomersal on dissociation of intact (146S) foot-and-mouth disease virions into 12S particles as assessed by novel ELISAs specific for either 146S or 12S particles Harmsen, M.M.
2011
29 Supplement 1 p. 2682-2690
9 p.
artikel
103 Efficacy of hepatitis B sero-vaccination in newborns of African HBsAg positive mothers Chakvetadze, Catherine
2011
29 Supplement 1 p. 2846-2849
4 p.
artikel
104 Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life Kawamura, Naohisa
2011
29 Supplement 1 p. 6335-6341
7 p.
artikel
105 Emerging and continuing trends in vaccine opposition website content Bean, Sandra J.
2011
29 Supplement 1 p. 1874-1880
7 p.
artikel
106 Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes Rosenkrands, Ida
2011
29 Supplement 1 p. 6283-6291
9 p.
artikel
107 Epidemiology and transmission dynamics of the 1918–19 pandemic influenza in Florence, Italy Rizzo, Caterina
2011
29 Supplement 1 p. B27-B32
nvt p.
artikel
108 Erratum to “Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1” [Vaccine 28 (42) (2010) 6901–6914] Gwinn, William M.
2011
29 Supplement 1 p. 2821-
1 p.
artikel
109 Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection Zheng, Qun
2011
29 Supplement 1 p. 763-771
9 p.
artikel
110 Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial Beckett, Charmagne G.
2011
29 Supplement 1 p. 960-968
9 p.
artikel
111 Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen Nagendrakumar, Singanallur Balasubramanian
2011
29 Supplement 1 p. 1906-1912
7 p.
artikel
112 Evaluation of Cryptococcus neoformans galactoxylomannan–protein conjugate as vaccine candidate against murine cryptococcosis Chow, Siu-Kei
2011
29 Supplement 1 p. 1891-1898
8 p.
artikel
113 Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products Parveen, Seema
2011
29 Supplement 1 p. 8012-8023
12 p.
artikel
114 Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities Tohme, Rania A.
2011
29 Supplement 1 p. 9316-9320
5 p.
artikel
115 Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-γ gene for immune protection against heterologous strains Shi, Xing-Ming
2011
29 Supplement 1 p. 1576-1582
7 p.
artikel
116 Evaluation of the genetic diversity of domain II of Plasmodium vivax Apical Membrane Antigen 1 (PvAMA-1) and the ensuing strain-specific immune responses in patients from Sri Lanka Dias, Sajani
2011
29 Supplement 1 p. 7491-7504
14 p.
artikel
117 Evaluation of the protective potential of a Taenia solium cysticercus mimotope on murine cysticercosis Capelli-Peixoto, Janaína
2011
29 Supplement 1 p. 9473-9479
7 p.
artikel
118 Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: Second report of the BCG-REVAC cluster-randomised trial Barreto, Mauricio L.
2011
29 Supplement 1 p. 4875-4877
3 p.
artikel
119 Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines Gil, Cristina
2011
29 Supplement 1 p. 5711-5724
14 p.
artikel
120 Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients Cotte, L.
2011
29 Supplement 1 p. 5638-5644
7 p.
artikel
121 Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial Aide, Pedro
2011
29 Supplement 1 p. 6059-6067
9 p.
artikel
122 From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine Guy, Bruno
2011
29 Supplement 1 p. 7229-7241
13 p.
artikel
123 Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins Visciano, M.L.
2011
29 Supplement 1 p. 4903-4912
10 p.
artikel
124 Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination Vrtala, Susanne
2011
29 Supplement 1 p. 2140-2148
9 p.
artikel
125 Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses Mantel, N.
2011
29 Supplement 1 p. 6629-6635
7 p.
artikel
126 α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model Jenikova, Gabriela
2011
29 Supplement 1 p. 9529-9537
9 p.
artikel
127 GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4+ T-independent CTL responses Nanjundappa, Roopa Hebbandi
2011
29 Supplement 1 p. 3538-3547
10 p.
artikel
128 Guillain–Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition Choe, Young June
2011
29 Supplement 1 p. 2066-2070
5 p.
artikel
129 Guillain–Barré Syndrome in India: Population-based validation of the Brighton criteria Mateen, Farrah J.
2011
29 Supplement 1 p. 9697-9701
5 p.
artikel
130 Hepatitis B immunity and vaccination coverage among young adult males in the Air Force in South Brazil Passos, Ana Maria
2011
29 Supplement 1 p. 9284-9288
5 p.
artikel
131 Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009 Lu, Peng-jun
2011
29 Supplement 1 p. 7049-7057
9 p.
artikel
132 Hepatitis B vaccination coverage in healthcare workers in Gauteng Province, South Africa Burnett, Rosemary J.
2011
29 Supplement 1 p. 4293-4297
5 p.
artikel
133 High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation Yin, Jiangmei
2011
29 Supplement 1 p. 6763-6770
8 p.
artikel
134 High burden of tick-borne encephalitis in Slovenia—Challenge for vaccination policy Grgič-Vitek, Marta
2011
29 Supplement 1 p. 5178-5183
6 p.
artikel
135 HIV fragment gag vaccine induces broader T cell response in mice Liu, Ye
2011
29 Supplement 1 p. 2582-2589
8 p.
artikel
136 HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line Tagliamonte, M.
2011
29 Supplement 1 p. 4913-4922
10 p.
artikel
137 Horizontal transmission of a human rotavirus vaccine strain—A randomized, placebo-controlled study in twins Rivera, Luis
2011
29 Supplement 1 p. 9508-9513
6 p.
artikel
138 Hospital-based study of the economic burden associated with rotavirus diarrhea in eastern China Jin, Hui
2011
29 Supplement 1 p. 7801-7806
6 p.
artikel
139 HPV vaccination in France: Uptake, costs and issues for the National Health Insurance Fagot, Jean-Paul
2011
29 Supplement 1 p. 3610-3616
7 p.
artikel
140 HPV vaccine and adolescent males Reiter, Paul L.
2011
29 Supplement 1 p. 5595-5602
8 p.
artikel
141 Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review Girard, Marc P.
2011
29 Supplement 1 p. 6191-6218
28 p.
artikel
142 Human papillomavirus vaccine initiation among adolescent girls in high-risk communities Guerry, Sarah L.
2011
29 Supplement 1 p. 2235-2241
7 p.
artikel
143 Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA Santamaria, Raquel
2011
29 Supplement 1 p. 8689-8695
7 p.
artikel
144 Humoral immunogenicity of an HIV-1 envelope residue 649–684 membrane-proximal region peptide fused to the plague antigen F1-V Matoba, Nobuyuki
2011
29 Supplement 1 p. 5584-5590
7 p.
artikel
145 Identification and immunogenicity of Mannheimia haemolytica S1 outer membrane lipoprotein PlpF Ayalew, Sahlu
2011
29 Supplement 1 p. 8712-8718
7 p.
artikel
146 Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites Mishra, Satish
2011
29 Supplement 1 p. 7335-7342
8 p.
artikel
147 Immune response of Atlantic salmon to recombinant flagellin Hynes, Natasha A.
2011
29 Supplement 1 p. 7678-7687
10 p.
artikel
148 Immune response of varicella vaccinees to different varicella-zoster virus genotypes Sauerbrei, A.
2011
29 Supplement 1 p. 3873-3877
5 p.
artikel
149 Immune responses to an attenuated West Nile virus NS4B-P38G mutant strain Welte, Thomas
2011
29 Supplement 1 p. 4853-4861
9 p.
artikel
150 Immunity against diphtheria among children and adults in Izmir, Turkey Kurugöl, Zafer
2011
29 Supplement 1 p. 4341-4344
4 p.
artikel
151 Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice Li, Yan-Li
2011
29 Supplement 1 p. 5959-5962
4 p.
artikel
152 Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis Garlapati, Srinivas
2011
29 Supplement 1 p. 6540-6548
9 p.
artikel
153 Immunization with the recombinant antigen Ss-IR induces protective immunity to infection with Strongyloides stercoralis in mice Abraham, David
2011
29 Supplement 1 p. 8134-8140
7 p.
artikel
154 Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys Maves, Ryan C.
2011
29 Supplement 1 p. 2691-2696
6 p.
artikel
155 Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP–IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea Lee, Soo Young
2011
29 Supplement 1 p. 1551-1557
7 p.
artikel
156 Immunogenicity and safety of a Haemophilus influenzae B (Hib)–hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants Lee, Andrew W.
2011
29 Supplement 1 p. 7942-7948
7 p.
artikel
157 Immunogenicity and safety of a measles–mumps–rubella–varicella vaccine following a 4-week or a 12-month interval between two doses Rümke, H.C.
2011
29 Supplement 1 p. 3842-3849
8 p.
artikel
158 Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children Saksawad, Rachanee
2011
29 Supplement 1 p. 4735-4738
4 p.
artikel
159 Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China Li, Rong Cheng
2011
29 Supplement 1 p. 1913-1920
8 p.
artikel
160 Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea Cheong, Hee Jin
2011
29 Supplement 1 p. 523-527
5 p.
artikel
161 Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children Phongsamart, Wanatpreeya
2011
29 Supplement 1 p. 8705-8711
7 p.
artikel
162 Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients Tremblay, Cécile L.
2011
29 Supplement 1 p. 1359-1363
5 p.
artikel
163 Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1–16 years Abarca, Katia
2011
29 Supplement 1 p. 8855-8862
8 p.
artikel
164 Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys Koeberling, Oliver
2011
29 Supplement 1 p. 4728-4734
7 p.
artikel
165 Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine Yan, Jian
2011
29 Supplement 1 p. 7173-7181
9 p.
artikel
166 Immunogenicity of conjugate Meningococcus C vaccine in pediatric solid organ transplant recipients Zlamy, Manuela
2011
29 Supplement 1 p. 6163-6166
4 p.
artikel
167 Immunogenicity of hepatitis B vaccine among hemodialysis patients: Effect of revaccination of non-responders and duration of protection Chaves, Sandra S.
2011
29 Supplement 1 p. 9618-9623
6 p.
artikel
168 Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration Cherif, Mahamoud Sama
2011
29 Supplement 1 p. 9038-9050
13 p.
artikel
169 Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006–2007 Anh, D.D.
2011
29 Supplement 1 p. 2029-2036
8 p.
artikel
170 Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation Dolter, Karen E.
2011
29 Supplement 1 p. 795-803
9 p.
artikel
171 Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized Miura, Kazutoyo
2011
29 Supplement 1 p. 2255-2261
7 p.
artikel
172 Impact of birth weight at term on rates of emergency room visits and hospital admissions following vaccination at 2 months of age Wilson, Kumanan
2011
29 Supplement 1 p. 8267-8274
8 p.
artikel
173 Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges Hanquet, Germaine
2011
29 Supplement 1 p. 2856-2864
9 p.
artikel
174 Impact of rotavirus vaccination on hospitalizations for rotavirus diarrhea: The IVANHOE study Gagneur, Arnaud
2011
29 Supplement 1 p. 3753-3759
7 p.
artikel
175 Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice Berhanu, Aklile
2010
29 Supplement 1 p. 289-303
15 p.
artikel
176 Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage Prymula, Roman
2011
29 Supplement 1 p. 1959-1967
9 p.
artikel
177 Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy Pozza, Francesca
2011
29 Supplement 1 p. 9480-9487
8 p.
artikel
178 Impaired hepatitis B vaccine responses during chronic hepatitis C infection: Involvement of the PD-1 pathway in regulating CD4+ T cell responses Moorman, Jonathan P.
2011
29 Supplement 1 p. 3169-3176
8 p.
artikel
179 Improvement of H5N1 influenza vaccine viruses: Influence of internal gene segments of avian and human origin on production and hemagglutinin content Abt, Marion
2011
29 Supplement 1 p. 5153-5162
10 p.
artikel
180 Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation Kumar, Rajnish
2011
29 Supplement 1 p. 9064-9074
11 p.
artikel
181 Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice Harada, Yuichi
2011
29 Supplement 1 p. 8330-8337
8 p.
artikel
182 Incorporation of immunostimulatory motifs in the transcribed region of a plasmid DNA vaccine enhances Th1 immune responses and therapeutic effect against Mycobacterium tuberculosis in mice Wu, Juan
2011
29 Supplement 1 p. 7624-7630
7 p.
artikel
183 Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response Moraes, Mauro Pires
2011
29 Supplement 1 p. 9431-9440
10 p.
artikel
184 Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity Hallengärd, David
2011
29 Supplement 1 p. 839-848
10 p.
artikel
185 Increasing vaccine potency through exosome antigen targeting Hartman, Zachary C.
2011
29 Supplement 1 p. 9361-9367
7 p.
artikel
186 Incremental costs of introducing jet injection technology for delivery of routine childhood vaccinations: Comparative analysis from Brazil, India, and South Africa Griffiths, Ulla K.
2011
29 Supplement 1 p. 969-975
7 p.
artikel
187 Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine Gabitzsch, Elizabeth S.
2011
29 Supplement 1 p. 8101-8107
7 p.
artikel
188 Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI) Taylor, David N.
2011
29 Supplement 1 p. 4897-4902
6 p.
artikel
189 Infection of mouse bone marrow-derived dendritic cells by live attenuated Japanese encephalitis virus induces cells maturation and triggers T cells activation Li, Yaoming
2011
29 Supplement 1 p. 855-862
8 p.
artikel
190 Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1 Brunelli, Brunella
2011
29 Supplement 1 p. 1072-1081
10 p.
artikel
191 International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations Barouch, Dan H.
2011
29 Supplement 1 p. 5203-5209
7 p.
artikel
192 Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine Velasquez, Lissette S.
2011
29 Supplement 1 p. 5221-5231
11 p.
artikel
193 Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms Donnelly, Louise
2011
29 Supplement 1 p. 4512-4520
9 p.
artikel
194 Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia Buttery, J.P.
2011
29 Supplement 1 p. 3061-3066
6 p.
artikel
195 Invasive pneumococcal disease in Catalonian elderly people, 2002–2009: Serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era Vila-Corcoles, Angel
2011
29 Supplement 1 p. 7430-7434
5 p.
artikel
196 Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines Ma, Hailun
2011
29 Supplement 1 p. 8429-8437
9 p.
artikel
197 “In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates”, NIAID Workshop Report, Bethesda, August 4, 2010 Malaspina, Angela
2011
29 Supplement 1 p. 4647-4653
7 p.
artikel
198 Kinetics of maternal antibodies against rubella and varicella in infants Leuridan, E.
2011
29 Supplement 1 p. 2222-2226
5 p.
artikel
199 Knockdown of the interleukin-6 receptor alpha chain of dendritic cell vaccines enhances the therapeutic potential against IL-6 producing tumors Hwang, Wonchan
2010
29 Supplement 1 p. 34-44
11 p.
artikel
200 Lights and shades on an historical vaccine canine distemper virus, the Rockborn strain Martella, V.
2011
29 Supplement 1 p. 1222-1227
6 p.
artikel
201 Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium) Lefevere, Eva
2011
29 Supplement 1 p. 8390-8396
7 p.
artikel
202 Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses Lanthier, Paula A.
2011
29 Supplement 1 p. 7849-7856
8 p.
artikel
203 Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines Capeding, Rosario Z.
2011
29 Supplement 1 p. 3863-3872
10 p.
artikel
204 Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51 Eder, Susanne
2011
29 Supplement 1 p. 2607-2612
6 p.
artikel
205 Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults Stermole, Benjamin M.
2011
29 Supplement 1 p. 2874-2880
7 p.
artikel
206 Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide® ISA 720 and stabilized with glycine Zhu, Daming
2011
29 Supplement 1 p. 3640-3645
6 p.
artikel
207 LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb Nawar, Hesham F.
2011
29 Supplement 1 p. 721-727
7 p.
artikel
208 Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers Rynkiewicz, Dianna
2011
29 Supplement 1 p. 6313-6320
8 p.
artikel
209 Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008 Shu, Min
2011
29 Supplement 1 p. 3507-3510
4 p.
artikel
210 MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68 Aricò, Eleonora
2011
29 Supplement 1 p. 3935-3944
10 p.
artikel
211 Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules Fraternale, Alessandra
2011
29 Supplement 1 p. 6823-6829
7 p.
artikel
212 Molecular and infectivity studies of porcine circovirus in vaccines McClenahan, Shasta D.
2011
29 Supplement 1 p. 4745-4753
9 p.
artikel
213 Monovalent type 1 oral poliovirus vaccine among infants in India: Report of two randomized double-blind controlled clinical trials John, T. Jacob
2011
29 Supplement 1 p. 5793-5801
9 p.
artikel
214 Mother–infant vaccination with pneumococcal polysaccharide vaccine: Persistence of maternal antibodies and responses of infants to vaccination Holmlund, Emma
2011
29 Supplement 1 p. 4565-4575
11 p.
artikel
215 Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: Revisiting the role of host innate susceptibility and routes of challenge Simon, Raphael
2011
29 Supplement 1 p. 5094-5106
13 p.
artikel
216 MtsB, a hydrophobic membrane protein of Streptococcus iniae, is an effective subunit vaccine candidate Zou, Lili
2011
29 Supplement 1 p. 391-394
4 p.
artikel
217 Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1 Wang, Ji
2011
29 Supplement 1 p. 8542-8548
7 p.
artikel
218 MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8+ T lymphocytes Mendes, Érica A.
2011
29 Supplement 1 p. 4476-4484
9 p.
artikel
219 Of mice and not humans: How reliable are animal models for evaluation of herpes CD8+-T cell-epitopes-based immunotherapeutic vaccine candidates? Dasgupta, Gargi
2011
29 Supplement 1 p. 5824-5836
13 p.
artikel
220 “Once Bitten, Twice Shy”: Participant perspectives in the aftermath of an early HIV vaccine trial termination Newman, P.A.
2011
29 Supplement 1 p. 451-458
8 p.
artikel
221 “Once I begin to participate, people will run away from me”: Understanding stigma as a barrier to HIV vaccine research participation in Kenya Nyblade, Laura
2011
29 Supplement 1 p. 8924-8928
5 p.
artikel
222 Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age Russell, F.M.
2011
29 Supplement 1 p. 535-544
10 p.
artikel
223 Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans Wu, Jiang
2011
29 Supplement 1 p. 1009-1016
8 p.
artikel
224 Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays Lorbetskie, Barry
2011
29 Supplement 1 p. 3377-3389
13 p.
artikel
225 Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice Cao, Jie
2011
29 Supplement 1 p. 3714-3723
10 p.
artikel
226 Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii McConnell, Michael J.
2011
29 Supplement 1 p. 5705-5710
6 p.
artikel
227 Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: Immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination Lagler, Heimo
2011
29 Supplement 1 p. 6888-6893
6 p.
artikel
228 Parental acceptance of human papillomavirus (HPV) vaccination in Indonesia: A cross-sectional study Jaspers, L.
2011
29 Supplement 1 p. 7785-7793
9 p.
artikel
229 Parental decline of pneumococcal vaccination and risk of pneumococcal related disease in children Glanz, Jason M.
2011
29 Supplement 1 p. 994-999
6 p.
artikel
230 Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques Marthas, Marta L.
2011
29 Supplement 1 p. 3124-3137
14 p.
artikel
231 Partial protection against classical swine fever virus elicited by dendrimeric vaccine-candidate peptides in domestic pigs Tarradas, Joan
2011
29 Supplement 1 p. 4422-4429
8 p.
artikel
232 Pathogenicity of SG 9R, a rough vaccine strain against fowl typhoid Kwon, Hyuk-Joon
2011
29 Supplement 1 p. 1311-1318
8 p.
artikel
233 Patterns of in vitro cell-death, metaloproteinase-9 and pro-inflammatory cytokines in human monocytes induced by the BCG vaccine, Moreau strain Simas, C.J.A.
2011
29 Supplement 1 p. 6446-6450
5 p.
artikel
234 Persistence of antibodies in 4–8 year old Austrian children after vaccination with hexavalent DTaP–HBV–IPV/Hib and MMR vaccines Paulke-Korinek, Maria
2011
29 Supplement 1 p. 5130-5136
7 p.
artikel
235 Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine Weston, Wayde
2011
29 Supplement 1 p. 8483-8486
4 p.
artikel
236 Pertussis after end of a mass vaccination project—End of the “vaccination honey-moon” Trollfors, Birger
2011
29 Supplement 1 p. 2444-2450
7 p.
artikel
237 Pertussis – An under-diagnosed disease with high morbidity in Singapore children Goh, Anne
2011
29 Supplement 1 p. 2503-2507
5 p.
artikel
238 Pharmacists as providers: Targeting pneumococcal vaccinations to high risk populations Taitel, Michael
2011
29 Supplement 1 p. 8073-8076
4 p.
artikel
239 Phenotypic variability in childhood TB: Implications for diagnostic endpoints in tuberculosis vaccine trials Mulenga, Humphrey
2011
29 Supplement 1 p. 4316-4321
6 p.
artikel
240 Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds Murata, Haruhiko
2011
29 Supplement 1 p. 3155-3161
7 p.
artikel
241 Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance van den Biggelaar, Anita H.J.
2011
29 Supplement 1 p. 5414-5420
7 p.
artikel
242 Pneumococcal disease manifestation in children before and after vaccination: What's new? Andrade, Ana Lucia
2011
29 Supplement 1 p. C2-C14
nvt p.
artikel
243 Pneumococcal serotype distribution and antimicrobial resistance in Chinese children hospitalized for pneumonia Yao, Kai-Hu
2011
29 Supplement 1 p. 2296-2301
6 p.
artikel
244 Polyfunctional analysis of Gag and Nef specific CD8+ T-cell responses in HIV-1 infected Indian individuals Mendiratta, Sanjay
2011
29 Supplement 1 p. 1150-1158
9 p.
artikel
245 Potential protective immunogenicity of recombinant Clostridium perfringens α–β2–β1 fusion toxin in mice, sows and cows Zeng, Jin
2011
29 Supplement 1 p. 5459-5466
8 p.
artikel
246 Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model Skinner, Julie M.
2011
29 Supplement 1 p. 8870-8876
7 p.
artikel
247 Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes Niu, Liguo
2011
29 Supplement 1 p. 2110-2119
10 p.
artikel
248 Predictors of hepatitis A vaccination among young children in the United States Byrd, Kathy K.
2011
29 Supplement 1 p. 3254-3259
6 p.
artikel
249 Preparation and identification of the lipopolysaccharide binding protein mimic epitope peptide vaccine that prevents endotoxin-induced acute lung injury in mice Feng, Yingkai
2011
29 Supplement 1 p. 4162-4172
11 p.
artikel
250 Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination Zhu, Chang-Lin
2011
29 Supplement 1 p. 7835-7841
7 p.
artikel
251 Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy Lao-araya, Mongkol
2011
29 Supplement 1 p. 3977-3981
5 p.
artikel
252 Prevention of pneumococcal disease through vaccination Gentile, Angela
2011
29 Supplement 1 p. C15-C25
nvt p.
artikel
253 Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines Quenee, Lauriane E.
2011
29 Supplement 1 p. 6572-6583
12 p.
artikel
254 Prime-boost immunisation against tropical theileriosis with two parasite surface antigens: Evidence for protection and antigen synergy Gharbi, Mohamed
2011
29 Supplement 1 p. 6620-6628
9 p.
artikel
255 Prime–boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges Lakhashe, Samir K.
2011
29 Supplement 1 p. 5611-5622
12 p.
artikel
256 Production and characterization of HCV particles from serum-free culture Akazawa, Daisuke
2011
29 Supplement 1 p. 4821-4828
8 p.
artikel
257 Productive infection of human hepatocellular carcinoma cells by porcine circovirus type 1 Beach, Nathan M.
2011
29 Supplement 1 p. 7303-7306
4 p.
artikel
258 Promoter control over foreign antigen expression in a murine cytomegalovirus vaccine vector Cunningham, Paula T.
2010
29 Supplement 1 p. 141-151
11 p.
artikel
259 Prospective pertussis surveillance in Switzerland, 1991–2006 Wymann, Monica N.
2011
29 Supplement 1 p. 2058-2065
8 p.
artikel
260 Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV types 1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus Xue, Wenzhi
2011
29 Supplement 1 p. 4657-4662
6 p.
artikel
261 Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain Minke, J.M.
2011
29 Supplement 1 p. 4608-4612
5 p.
artikel
262 Protective immunity to ricin toxin conferred by antibodies against the toxin's binding subunit (RTB) Yermakova, Anastasiya
2011
29 Supplement 1 p. 7925-7935
11 p.
artikel
263 Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development Yuan, Tingting
2011
29 Supplement 1 p. 6903-6910
8 p.
artikel
264 Quantitative assessment of masking of neutralization epitopes in HIV-1 Agarwal, Alpna
2011
29 Supplement 1 p. 6736-6741
6 p.
artikel
265 Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression Bunupuradah, Torsak
2011
29 Supplement 1 p. 2962-2967
6 p.
artikel
266 Reasons related to non-vaccination and under-vaccination of children in low and middle income countries: Findings from a systematic review of the published literature, 1999–2009 Rainey, Jeanette J.
2011
29 Supplement 1 p. 8215-8221
7 p.
artikel
267 RecNcMIC3-1-R is a microneme- and rhoptry-based chimeric antigen that protects against acute neosporosis and limits cerebral parasite load in the mouse model for Neospora caninum infection Monney, Thierry
2011
29 Supplement 1 p. 6967-6975
9 p.
artikel
268 Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: No evidence of hyporesponsiveness Hammitt, Laura L.
2011
29 Supplement 1 p. 2287-2295
9 p.
artikel
269 Report of an International collaborative study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains Ho, Mei M.
2011
29 Supplement 1 p. 512-518
7 p.
artikel
270 Response to hepatitis B vaccine differs by birthweight among neonates Çekmez, Ferhat
2011
29 Supplement 1 p. 3096-3097
2 p.
artikel
271 Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: A database study Stowe, Julia
2011
29 Supplement 1 p. 9467-9472
6 p.
artikel
272 Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age Ray, Paula
2011
29 Supplement 1 p. 6592-6597
6 p.
artikel
273 Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: Association with mucoadhesion and efficient penetration of the sublingual barrier Domm, William
2011
29 Supplement 1 p. 7080-7089
10 p.
artikel
274 Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) García, Felipe
2011
29 Supplement 1 p. 8309-8316
8 p.
artikel
275 Safety and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in healthy adults Turley, Christine B.
2011
29 Supplement 1 p. 5145-5152
8 p.
artikel
276 Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: A phase III open-label single-arm study Loebermann, M.
2011
29 Supplement 1 p. 1228-1234
7 p.
artikel
277 Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico López-Macías, Constantino
2011
29 Supplement 1 p. 7826-7834
9 p.
artikel
278 Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age Diaz-Mitoma, Francisco
2011
29 Supplement 1 p. 1324-1331
8 p.
artikel
279 Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age Saha, Amit
2011
29 Supplement 1 p. 8285-8292
8 p.
artikel
280 Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome Liakou, Christina D.
2011
29 Supplement 1 p. 6834-6837
4 p.
artikel
281 Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance Kurz, Xavier
2011
29 Supplement 1 p. 4378-4387
10 p.
artikel
282 School-located immunization programs: Do parental preferences predict behavior? Middleman, Amy B.
2011
29 Supplement 1 p. 3513-3516
4 p.
artikel
283 Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148) 2011
29 Supplement 1 p. 4285-4292
8 p.
artikel
284 Screening and identification of T helper 1 and linear immunodominant antibody-binding epitopes in the spike 2 domain and the nucleocapsid protein of feline infectious peritonitis virus Satoh, Ryoichi
2011
29 Supplement 1 p. 1791-1800
10 p.
artikel
285 Seasonal influenza vaccination in adults: Practice and attitudes about collaborative delivery with community vaccinators Hurley, Laura P.
2011
29 Supplement 1 p. 8649-8655
7 p.
artikel
286 Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths Alexander, Neal
2011
29 Supplement 1 p. 3686-3694
9 p.
artikel
287 Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells Goulart, Cibelly
2011
29 Supplement 1 p. 1634-1642
9 p.
artikel
288 Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS) Poethko-Müller, Christina
2011
29 Supplement 1 p. 7949-7959
11 p.
artikel
289 Sero-prevalence of mumps antibodies in subpopulations subsequently affected by a large scale mumps epidemic in Israel Muhsen, Khitam
2011
29 Supplement 1 p. 3878-3882
5 p.
artikel
290 Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000–2007 Menezes, Ana Paula de O.
2011
29 Supplement 1 p. 1139-1144
6 p.
artikel
291 Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months Russell, F.M.
2011
29 Supplement 1 p. 4499-4506
8 p.
artikel
292 Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6–59 months of age Mallory, Raburn M.
2011
29 Supplement 1 p. 4322-4327
6 p.
artikel
293 Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library Neri, Paola
2011
29 Supplement 1 p. 5340-5346
7 p.
artikel
294 Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus Hwang, Seon Do
2011
29 Supplement 1 p. 2178-2186
9 p.
artikel
295 Smallpox eradication in Bangladesh, 1972–1976 Foster, Stanley O.
2011
29 Supplement 1 p. D22-D29
nvt p.
artikel
296 Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009–March 2010 Folkenberg, Maja
2011
29 Supplement 1 p. 1180-1184
5 p.
artikel
297 Stability of seasonal influenza vaccines investigated by spectroscopy and microscopy methods Patois, E.
2011
29 Supplement 1 p. 7404-7413
10 p.
artikel
298 Strategies for improved stability of Peste des Petits Ruminants Vaccine Silva, Ana Carina
2011
29 Supplement 1 p. 4983-4991
9 p.
artikel
299 Strengthening the technical capacity at country-level to make informed policy decisions on new vaccine introduction: Lessons learned by PAHO's ProVac Initiative Jauregui, Barbara
2011
29 Supplement 1 p. 1099-1106
8 p.
artikel
300 Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells Sistigu, A.
2011
29 Supplement 1 p. 3465-3475
11 p.
artikel
301 Subcutaneous and intranasal immunization with Stx2B–Tir–Stx1B–Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice Zhang, Xue-han
2011
29 Supplement 1 p. 3923-3929
7 p.
artikel
302 Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine Zhang, Wei
2011
29 Supplement 1 p. 6276-6282
7 p.
artikel
303 Swine adipose stromal cells loaded with recombinant bovine herpesvirus 4 virions expressing a foreign antigen induce potent humoral immune responses in pigs Donofrio, Gaetano
2011
29 Supplement 1 p. 867-872
6 p.
artikel
304 Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses Liard, Christelle
2011
29 Supplement 1 p. 6379-6391
13 p.
artikel
305 Telephone survey assessment of household patterns of influenza vaccination, Twin Cities seven county metro area, 2008–2009 Robien, Mark A.
2011
29 Supplement 1 p. 4033-4042
10 p.
artikel
306 The current status of invasive pneumococcal disease in Poland Skoczyńska, Anna
2011
29 Supplement 1 p. 2199-2205
7 p.
artikel
307 The effect of influenza vaccination on risk of acute myocardial infarction: Self-controlled case-series study Gwini, Stella M.
2011
29 Supplement 1 p. 1145-1149
5 p.
artikel
308 The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination Parvanova, Iana
2011
29 Supplement 1 p. 3832-3836
5 p.
artikel
309 The future of pneumococcal disease prevention Rodgers, Gail L.
2011
29 Supplement 1 p. C43-C48
nvt p.
artikel
310 The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic Engelhard, Dan
2011
29 Supplement 1 p. 1777-1782
6 p.
artikel
311 The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children Thanee, Chareeya
2011
29 Supplement 1 p. 5886-5891
6 p.
artikel
312 The impact of additional pertussis vaccine doses on disease incidence in children and infants Stein-Zamir, Chen
2010
29 Supplement 1 p. 207-211
5 p.
artikel
313 The 1918 influenza pandemic in Florianopolis: A subtropical city in Brazil Alonso, Wladimir J.
2011
29 Supplement 1 p. B16-B20
nvt p.
artikel
314 The introduction of multi-copy CpG motifs into an antiviral DNA vaccine strongly up-regulates its immunogenicity in fish Martinez-Alonso, S.
2011
29 Supplement 1 p. 1289-1296
8 p.
artikel
315 The optimal number of routine vaccines to order at health clinics in low or middle income countries Rajgopal, Jayant
2011
29 Supplement 1 p. 5512-5518
7 p.
artikel
316 The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children Palma, Paolo
2011
29 Supplement 1 p. 6810-6816
7 p.
artikel
317 The perils of using annual all-cause mortality data to estimate pandemic influenza burden Andreasen, Viggo
2011
29 Supplement 1 p. B49-B55
nvt p.
artikel
318 The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results Andersson, Kyeen M.
2011
29 Supplement 1 p. 6107-6112
6 p.
artikel
319 Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: A Phase I safety study Kityo, Cissy
2011
29 Supplement 1 p. 1617-1623
7 p.
artikel
320 The recombinant gut-associated M17 leucine aminopeptidase in combination with different adjuvants confers a high level of protection against Fasciola hepatica infection in sheep Maggioli, Gabriela
2011
29 Supplement 1 p. 9057-9063
7 p.
artikel
321 Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose Klugman, K.P.
2011
29 Supplement 1 p. 3372-3373
2 p.
artikel
322 Towards an immunosense vaccine to prevent toxoplasmosis: Protective Toxoplasma gondii epitopes restricted by HLA-A*0201 Cong, Hua
2011
29 Supplement 1 p. 754-762
9 p.
artikel
323 Transgenic Neospora caninum strains constitutively expressing the bradyzoite NcSAG4 protein proved to be safe and conferred significant levels of protection against vertical transmission when used as live vaccines in mice Marugán-Hernández, V.
2011
29 Supplement 1 p. 7867-7874
8 p.
artikel
324 Trends in US pediatric influenza vaccination from 2006 to 2010 among children with private insurance Toback, Seth L.
2011
29 Supplement 1 p. 4225-4229
5 p.
artikel
325 Trivalent influenza vaccine and febrile adverse events in Australia, 2010: Clinical features and potential mechanisms Blyth, C.C.
2011
29 Supplement 1 p. 5107-5113
7 p.
artikel
326 Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model Kollessery, Gayathri
2011
29 Supplement 1 p. 5904-5910
7 p.
artikel
327 Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults Hatakeyama, Shuji
2011
29 Supplement 1 p. 9224-9228
5 p.
artikel
328 Updated aluminum pharmacokinetics following infant exposures through diet and vaccination Mitkus, Robert J.
2011
29 Supplement 1 p. 9538-9543
6 p.
artikel
329 Uptake of various yeast genera by antigen-presenting cells and influence of subcellular antigen localization on the activation of ovalbumin-specific CD8 T lymphocytes Bazan, Silvia Boschi
2011
29 Supplement 1 p. 8165-8173
9 p.
artikel
330 Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country Biai, Sidu
2011
29 Supplement 1 p. 3662-3669
8 p.
artikel
331 Vaccination with a modified-live bovine viral diarrhea virus (BVDV) type 1a vaccine completely protected calves against challenge with BVDV type 1b strains Xue, Wenzhi
2010
29 Supplement 1 p. 70-76
7 p.
artikel
332 Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus Loeffen, W.L.A.
2011
29 Supplement 1 p. 1545-1550
6 p.
artikel
333 Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus Santiago, Felix W.
2011
29 Supplement 1 p. 8888-8897
10 p.
artikel
334 Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction Smirnov, Dmitri
2011
29 Supplement 1 p. 5434-5442
9 p.
artikel
335 Vaccine counseling: A content analysis of patient–physician discussions regarding human papilloma virus vaccine Goff, Sarah L.
2011
29 Supplement 1 p. 7343-7349
7 p.
artikel
336 Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response Charles-Niño, Claudia
2011
29 Supplement 1 p. 5313-5321
9 p.
artikel
337 Voluntary reporting of employee influenza vaccination rates by acute care hospitals in Iowa: The impact of a four year provider-based statewide performance improvement project Helms, Charles
2011
29 Supplement 1 p. 3483-3488
6 p.
artikel
338 Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice Chauhan, Neelima B.
2011
29 Supplement 1 p. 7631-7637
7 p.
artikel
                             338 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland